Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Minimal Residual Disease in Acute Myeloid Leukemia

Minimal Residual Disease in Acute Myeloid Leukemia Association of Measurable Residual Disease With Survival in Patients With Acute Myeloid Leukemia Original Investigation Research 94. Manara E, Basso G, Zampini M, et al. Leukemia. 2018;32(1):241-244. doi:10.1038/leu. improve outcomes of t(8;21) AML in the first Characterization of children with FLT3-ITD acute 2017.285 complete remission: results from the AML05 myeloid leukemia: a report from the AIEOP multicenter trial. Blood. 2013;121(20):4056-4062. 101. Lacombe F, Campos L, Allou K, et al; Groupe AML-2002 study group. Leukemia. 2017;31(1):18-25. doi:10.1182/blood-2012-11-468348 d’Etude Immunologique des Leucémies (GEIL). doi:10.1038/leu.2016.177 Prognostic value of multicenter flow cytometry 109. Hourigan CS, Dillon LW, Gui G, et al. Impact of 95. Huang S, Yang H, Li Y, et al. Prognostic harmonized assessment of minimal residual disease conditioning intensity of allogeneic transplantation significance of mixed-lineage leukemia (MLL) gene in acute myeloblastic leukemia. Hematol Oncol. for acute myeloid leukemia with genomic evidence detected by real-time fluorescence quantitative 2018;36(2):422-428. doi:10.1002/hon.2488 of residual disease. J Clin Oncol. 2020;38(12): PCR assay in acute myeloid leukemia. Med Sci Monit. 1273-1283. doi:10.1200/JCO.19.03011 102. Ferret Y, Boissel N, Helevaut N, et al. Clinical 2016;22:3009-3017. doi:10.12659/MSM.900429 relevance of IDH1/2 mutant allele burden during 110. Sockel K, Wermke M, Radke J, et al. Minimal 96. Buldini B, Rizzati F, Masetti http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Minimal Residual Disease in Acute Myeloid Leukemia

JAMA Oncology , Volume 6 (12) – Dec 8, 2020

Loading next page...
 
/lp/american-medical-association/minimal-residual-disease-in-acute-myeloid-leukemia-yjJ1oeb07J
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.4599
Publisher site
See Article on Publisher Site

Abstract

Association of Measurable Residual Disease With Survival in Patients With Acute Myeloid Leukemia Original Investigation Research 94. Manara E, Basso G, Zampini M, et al. Leukemia. 2018;32(1):241-244. doi:10.1038/leu. improve outcomes of t(8;21) AML in the first Characterization of children with FLT3-ITD acute 2017.285 complete remission: results from the AML05 myeloid leukemia: a report from the AIEOP multicenter trial. Blood. 2013;121(20):4056-4062. 101. Lacombe F, Campos L, Allou K, et al; Groupe AML-2002 study group. Leukemia. 2017;31(1):18-25. doi:10.1182/blood-2012-11-468348 d’Etude Immunologique des Leucémies (GEIL). doi:10.1038/leu.2016.177 Prognostic value of multicenter flow cytometry 109. Hourigan CS, Dillon LW, Gui G, et al. Impact of 95. Huang S, Yang H, Li Y, et al. Prognostic harmonized assessment of minimal residual disease conditioning intensity of allogeneic transplantation significance of mixed-lineage leukemia (MLL) gene in acute myeloblastic leukemia. Hematol Oncol. for acute myeloid leukemia with genomic evidence detected by real-time fluorescence quantitative 2018;36(2):422-428. doi:10.1002/hon.2488 of residual disease. J Clin Oncol. 2020;38(12): PCR assay in acute myeloid leukemia. Med Sci Monit. 1273-1283. doi:10.1200/JCO.19.03011 102. Ferret Y, Boissel N, Helevaut N, et al. Clinical 2016;22:3009-3017. doi:10.12659/MSM.900429 relevance of IDH1/2 mutant allele burden during 110. Sockel K, Wermke M, Radke J, et al. Minimal 96. Buldini B, Rizzati F, Masetti

Journal

JAMA OncologyAmerican Medical Association

Published: Dec 8, 2020

References